Effect of an Extract From the Wine Industry on Blood Pressure (HYPERGRAPES) (HYPERGRAPES)
Primary Purpose
Cardiovascular Diseases, Hypertension
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Extract from the wine industry
Placebo
Sponsored by

About this trial
This is an interventional prevention trial for Cardiovascular Diseases focused on measuring Blood pressure, wine, by-products
Eligibility Criteria
Inclusion Criteria:
- Men and women over 18 years of age.
- Systolic blood pressure between 130- 159 mm Hg.
- Not under pharmacological treatment or have completed pharmacological treatment at least one month before the start of the study with anti-hypertensive and/or with lipid-lowering drugs. 2. Sign the informed consent.
Exclusion Criteria:
- BMI ≥ 35 kg/m^2.
- Have a clinical history of chronic kidney disease, cardiovascular disease and/or cancer.
- Be a smoker or ex-smoker in the last 6 months before inclusion in the study.
- Present diabetes.
- Take supplements with polyphenol components or aimed to lipid or blood pressure control during their participation in the study.
- Take 2 or more Standard Beverage Units daily or 17 weekly for women, or take 4 or more Standard Beverage Units daily or 28 weekly for men.
- Present some chronic gastrointestinal disease.
- Present food intolerances and/or allergies related to the products of the study, such as hypersensitivity to maltodextrin and/or sulfites.
- Being pregnant or intending to become pregnant.
- Be in breastfeeding period.
- Participate in or have participated in a clinical trial with drugs or nutritional intervention study in the last 30 days prior to inclusion in the study.
- Being unable to follow the study guidelines.
Sites / Locations
- Eurecat
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Extract from the wine industry
Placebo
Arm Description
Participants will consume the extract from the wine industry for 5 weeks.
Participants will consume maltodextrin for 5 weeks.
Outcomes
Primary Outcome Measures
Change in systolic blood pressure
Systolic blood pressure will be measured using an automatic sphygmomanometer.
Secondary Outcome Measures
Change in diastolic blood pressure
Diastolic blood pressure will be measured using an automatic sphygmomanometer.
Change in body weight
Body weight measured by standardized method.
Height
Height measured by standardized method.
Change in BMI
Weight and height will be combined to report BMI in kg/m^2.
Changes in waist circumference
Waist circumference using a measuring tape.
Changes in conicity index
Weight, height and waist circumference will be combined to report Conicity index.
Changes in waist circumference to height ratio
Waist circumference and height will be combined to report Waist circumference to Height ratio.
Changes in serum glucose levels
Serum glucose levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Changes in serum insulin levels
Serum insulin levels will be measured by standardized chemiluminescence methods.
Changes in Homeostatic Model Assessment from Insulin Resistance Index (HOMA-IR)
HOMA-IR will be calculated using serum glucose and insulin levels.
Changes in serum total cholesterol levels.
Serum total cholesterol levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Changes in serum HDL-c levels.
Serum HDL-c levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Changes in serum LDL-c levels.
Serum LDL-c levels will be calculated using the Friedewald formula.
Changes in serum Triglycerides levels
Serum triglycerides levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Changes in total cholesterol to HDL-c ratio
Total cholesterol and HDL-c values will be combined to report Total cholesterol to HDL-c ratio.
Changes in LDL-c to HDL-c ratio
LDL-c and HDL-c values will be combined to report LDL-c to HDL-c ratio.
Changes in Plasma atherogenic index
Plasma atherogenic index will be calculated as the logarithm of the TG to HDL-c ratio.
Changes in serum Apo B levels
Serum Apo B levels will be measured by standardized turbidimetry methods.
Changes in serum C- Reactive protein levels
Serum C-Reactive protein levels will be measured by standardized turbidimetry methods.
Changes in intestinal microbiota composition
Metagenomic analysis in fecal samples. The bacteria DNA will be extracted and massive sequenced by the Ion Torrent platform.
Change in Physical activity
Physical activity will be evaluated through the International Physical Activity. Questionnaire (IPAQ)-short for physical activity questionnaire. The questionnaire asks about three specific types of activity (walking, moderate-intensity activities and vigorous intensity activities) in the set domains leisure time, domestic and gardening (yard) activities, work-related and transport-related activities. Frequency and duration are collected separately for each specific type of activity.
Adverse events
Possible adverse events derived from taking study's products will be recorded.
Full Information
NCT ID
NCT04992936
First Posted
July 24, 2021
Last Updated
March 14, 2023
Sponsor
Fundació Eurecat
Collaborators
University Rovira i Virgili, Grandes Vinos y Viñedos S.A.
1. Study Identification
Unique Protocol Identification Number
NCT04992936
Brief Title
Effect of an Extract From the Wine Industry on Blood Pressure (HYPERGRAPES)
Acronym
HYPERGRAPES
Official Title
Effect of an Alcohol-Free Extract From the Wine Industry on Blood Pressure in Individuals With High Blood Pressure and Grade 1 Hypertension. Randomized, Crossover, Controlled Double Blind Study
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
August 26, 2021 (Actual)
Primary Completion Date
June 22, 2022 (Actual)
Study Completion Date
June 22, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundació Eurecat
Collaborators
University Rovira i Virgili, Grandes Vinos y Viñedos S.A.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
By-products from the wine industry pose serious problems of management, both from an economic and environmental point of view. Although traditionally the use of by-products of the wine sector has been limited to the production of biogas and energy, or its use as animal feed or agricultural fertilizer, there is greater interest in the use of these by-products as a potential source of functional ingredients.
Cardiovascular diseases (CVD) are the main cause of mortality in Europe, with hypertension being one of the main CVD risk factors. It has been shown that lowering blood pressure through behavioral and pharmacological interventions significantly improves CVD. Currently, one of the most widely used pharmacological therapies to treat hypertension is based on the use of angiotensin converting enzyme (ACE) inhibitors such as Captopril or Enalapril. ACE plays a key role in arterial pressure regulation, catalyzing the production of angiotensin II, an octapeptide with potent vasoconstrictor activity. In addition, ACE catalyzes the inactivation of bradykinin, peptide with vasodilator activity. The evaluation of various potential by-products of the wine industry for the generation of functional ingredients showed that an extract from the wine industry presented beneficial effects on blood pressure in in vitro models as well as in vivo models using rats with hypertension.
Detailed Description
The main objective of the study is to evaluate the effect of daily intake of an extract from the wine industry on the change in systolic blood pressure values in individuals with high blood pressure and grade 1 hypertension.
Secondary objectives are to evaluate the effects of an extract from the wine industry on:
The change in diastolic blood pressure values.
The change in body weight, body mass index (BMI) and waist circumference.
The change in the circulating values of total cholesterol, LDL-c, HDL-c, triglycerides and ApoB.
The change in the atherogenic index of plasma, which combines triglycerides and HDL-c values and which is considered a good indirect indicator of LDL-c particle size and subclinical atherosclerosis.
Glucose metabolism and insulin resistance.
The change in the inflammation values analyzed by the marker high sensitivity C-reactive protein.
Study Design: Randomized, crossover, placebo-controlled and double-blind nutritional intervention trial.
The number of subjects in the study will be 40. After the pre-screening visit, the participants will be randomly divided into two groups of 20 participants, according to start the study by taking the extract from the wine industry or placebo for 5 weeks. At the end of the week 5 of the study, when the first treatment is finished, there will be a washing period for 3 weeks and then the treatment will be changed for another 5 weeks: a total of 14 weeks.
The containers of the two treatments, the extract from the wine industry and the placebo, will present the same shape and appearance. The two products will present similar organoleptic characteristics of taste and color.
Each volunteer will make 5 visits, according to the crossover study design:
a pre-selection visit (to check inclusion / exclusion criteria) (V0; week1) and, in case of meeting the inclusion criteria,
two study visits during the consumption of the first product (extract from the wine industry or placebo), which will take place on the first day of study (V1; week 2) and after 5 weeks of treatment (V2; week 7).
two study visits during the consumption of the second product (extract from the wine industry or placebo), which will take place after the three week washout period (V3; week 10) and after 5 weeks of treatment (V4; week 15).
In all visits except the V0 visit, participants must present themselves in fasting conditions of 8 hours to obtain blood. In addition, on V2 visits and V4 the participants will be asked the presence / absence of adverse effects that could be associated with the consumption of the study products.
Main variable: Systolic blood pressure levels.
Secondary variables:
Diastolic blood pressure levels.
Body weight.
Height.
Body mass index (BMI) (Kg/m2).
Waist circumference.
Conicity index.
Waist circumference/Height ratio.
Parameters in serum:
Glucose.
Insulin.
Homeostatic Model Assessment for insulin resistance index (HOMA-IR).
Total cholesterol.
High density lipoproteins cholesterol (HDL-c).
Low density lipoproteins cholesterol (LDL-c).
Triglycerides (TG).
Atherogenic indices:
Total cholesterol/HDL-c
LDL-c/HDL-c
Plasma atherogenic index, calculated as the logarithm of the TG/HDL-c ratio.
Apolipoprotein (apo) B.
C-reactive protein.
Faecal intestinal microbiota composition.
Physical activity record.
Record of potential adverse events.
Frequency of consumption of supplements to avoid in the study.
Completion of the intervention.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Diseases, Hypertension
Keywords
Blood pressure, wine, by-products
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
41 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Extract from the wine industry
Arm Type
Experimental
Arm Description
Participants will consume the extract from the wine industry for 5 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will consume maltodextrin for 5 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Extract from the wine industry
Intervention Description
The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
Primary Outcome Measure Information:
Title
Change in systolic blood pressure
Description
Systolic blood pressure will be measured using an automatic sphygmomanometer.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Secondary Outcome Measure Information:
Title
Change in diastolic blood pressure
Description
Diastolic blood pressure will be measured using an automatic sphygmomanometer.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Change in body weight
Description
Body weight measured by standardized method.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Height
Description
Height measured by standardized method.
Time Frame
At week 1.
Title
Change in BMI
Description
Weight and height will be combined to report BMI in kg/m^2.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in waist circumference
Description
Waist circumference using a measuring tape.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in conicity index
Description
Weight, height and waist circumference will be combined to report Conicity index.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in waist circumference to height ratio
Description
Waist circumference and height will be combined to report Waist circumference to Height ratio.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in serum glucose levels
Description
Serum glucose levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in serum insulin levels
Description
Serum insulin levels will be measured by standardized chemiluminescence methods.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in Homeostatic Model Assessment from Insulin Resistance Index (HOMA-IR)
Description
HOMA-IR will be calculated using serum glucose and insulin levels.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in serum total cholesterol levels.
Description
Serum total cholesterol levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in serum HDL-c levels.
Description
Serum HDL-c levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in serum LDL-c levels.
Description
Serum LDL-c levels will be calculated using the Friedewald formula.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in serum Triglycerides levels
Description
Serum triglycerides levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in total cholesterol to HDL-c ratio
Description
Total cholesterol and HDL-c values will be combined to report Total cholesterol to HDL-c ratio.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in LDL-c to HDL-c ratio
Description
LDL-c and HDL-c values will be combined to report LDL-c to HDL-c ratio.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in Plasma atherogenic index
Description
Plasma atherogenic index will be calculated as the logarithm of the TG to HDL-c ratio.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in serum Apo B levels
Description
Serum Apo B levels will be measured by standardized turbidimetry methods.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in serum C- Reactive protein levels
Description
Serum C-Reactive protein levels will be measured by standardized turbidimetry methods.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Changes in intestinal microbiota composition
Description
Metagenomic analysis in fecal samples. The bacteria DNA will be extracted and massive sequenced by the Ion Torrent platform.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Change in Physical activity
Description
Physical activity will be evaluated through the International Physical Activity. Questionnaire (IPAQ)-short for physical activity questionnaire. The questionnaire asks about three specific types of activity (walking, moderate-intensity activities and vigorous intensity activities) in the set domains leisure time, domestic and gardening (yard) activities, work-related and transport-related activities. Frequency and duration are collected separately for each specific type of activity.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
Title
Adverse events
Description
Possible adverse events derived from taking study's products will be recorded.
Time Frame
Before (baseline) and after treatment period (5 weeks) for each of the two treatments (dry VLC and placebo).
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Men and women over 18 years of age.
Systolic blood pressure between 130- 159 mm Hg.
Not under pharmacological treatment or have completed pharmacological treatment at least one month before the start of the study with anti-hypertensive and/or with lipid-lowering drugs. 2. Sign the informed consent.
Exclusion Criteria:
BMI ≥ 35 kg/m^2.
Have a clinical history of chronic kidney disease, cardiovascular disease and/or cancer.
Be a smoker or ex-smoker in the last 6 months before inclusion in the study.
Present diabetes.
Take supplements with polyphenol components or aimed to lipid or blood pressure control during their participation in the study.
Take 2 or more Standard Beverage Units daily or 17 weekly for women, or take 4 or more Standard Beverage Units daily or 28 weekly for men.
Present some chronic gastrointestinal disease.
Present food intolerances and/or allergies related to the products of the study, such as hypersensitivity to maltodextrin and/or sulfites.
Being pregnant or intending to become pregnant.
Be in breastfeeding period.
Participate in or have participated in a clinical trial with drugs or nutritional intervention study in the last 30 days prior to inclusion in the study.
Being unable to follow the study guidelines.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Josep M Del Bas, PhD
Organizational Affiliation
UTNS (Eurecat-Reus)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Eurecat
City
Reus
ZIP/Postal Code
43204
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD will be shared with the Universitat Rovira i Virgili for the intestinal microbiota composition analysis
IPD Sharing Time Frame
The data will be shared once the intervention period with the study participants has finished and will be shared until the end of the study analysis.
IPD Sharing Access Criteria
The data will be encoded and access to the data will be controlled to only authorized personnel.
Links:
URL
http://eurecat.org
Description
Technological Centre of Nutrition and Health. Eurecat_Reus.
Learn more about this trial
Effect of an Extract From the Wine Industry on Blood Pressure (HYPERGRAPES)
We'll reach out to this number within 24 hrs